Battle Over Deferred Drug Listings In Australia: Should Cost-Effective Drugs Always Be Funded?
This article was originally published in The Pink Sheet Daily
Executive Summary
Much to the chagrin of industry, Health Minister Roxon has announced that the Cabinet will now make all decisions about what drugs are listed on the federal drug plan, regardless of price.
You may also be interested in...
Medicines Australia Negotiates Lower Off-patent Prices In Exchange For Level Prices For Innovative New Drugs In Newly Announced Federal Budget
PERTH, Australia - As part of the new federal budget announced May 11, Medicines Australia has negotiated price-saving measures with the Australian government that will cut prices on off-patent medicines in exchange for an assurance from the government that innovative prices on drugs will not be cut for four years
Australia Has Cheapest Drugs Compared To OECD Countries, UK Says
PERTH, Australia - Australia has the lowest prices for new medicines among developed countries, according to a UK Department of Health report on the Pharmaceutical Price Regulation Scheme
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.